Chicago-based Prenosis recognized for pushing the boundaries of biology and AI in acute care innovation
CHICAGO, IL – September 24, 2025 – Prenosis has been named one of the Top 100 Finalists for the 24th Annual Chicago Innovation Awards, which celebrates the most innovative new products and services in the Chicago region across all industries. Over 700 business and civic leaders will gather to honor the winners when they are announced on November 13, 2025, at the University of Illinois Chicago Forum.
Prenosis earned this recognition for its Sepsis ImmunoScore™, the first and only FDA-authorized AI diagnostic tool for sepsis, developed on the company’s Immunix™ platform. Sepsis ImmunoScore combines biomarkers and clinical data to generate real-time, predictive insights into sepsis risk, helping clinicians make more confident decisions when time is critical.
“Being named a Top 100 Finalist in the Chicago Innovation Awards is an exciting moment for our team and for the Chicago innovation ecosystem,” said Bobby Reddy, Jr., PhD, co-founder and CEO of Prenosis. “This honor recognizes the hard work of our scientists, engineers, and collaborators who are committed to using biology and AI to illuminate some of the most challenging problems in critical care.”
Each finalist is also in the running for the annual People’s Choice Award, which invites the public to vote for their favorite innovation of the year. Voting is open now through Friday, October 9 at chicagoinnovation.com/nominations.
“Chicago continues to rise as a global hub of innovation that cuts across industries, large corporations and startups, for-profits and non-profits,” said Luke Tanen, president and CEO of Chicago Innovation. “The impact that this year’s nominees generated is profound; their new products and services generated $4.2 billion in revenues and created over 2,300 new jobs.”
Out of the Top 100 Finalists, a panel of judges will select 20 winners of the Chicago Innovation Awards. In addition to being celebrated at the awards ceremony, winners will be invited to ring the NASDAQ Bell in New York City and will receive widespread media recognition.
About Prenosis, Inc.
Prenosis, Inc. is a biology-based technology company redefining the standard of care for critical conditions. We believe healthcare should not follow a one-size-fits-all model. Instead, our mission is to tailor healthcare to each patient’s biology through the creation and delivery of integrated diagnostics and therapeutics. We use deep data and AI to build tools that augment clinical diagnosis of critical conditions based on each patient’s unique biological profile. Unlike other AI-driven diagnostics, we go further by developing therapies that help providers deliver personalized care. Our Immunix™ platform powers the development of a variety of AI-based diagnostics, including Sepsis ImmunoScore™, the first FDA-authorized AI diagnostic tool for sepsis. At Prenosis, we see people differently. For more information, visit us on LinkedIn.
About Chicago Innovation
Chicago Innovation is the largest annual celebration of new products, services, and business models in the region. Since 2002, it has connected entrepreneurs, corporate leaders, investors, and civic partners to showcase Chicago as a global hub of innovation through its flagship awards program and year-round events. Learn more at chicagoinnovation.com.